Rigel Pharmaceuticals Inc
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report2 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
+4.60%
vs ±12.9% implied · ×0.36
shaded = implied · ▲▼ = realized
Rigel Pharmaceuticals has 6 disclosed suppliers and 13 disclosed customers in SEC filings.
Rigel Pharmaceuticals Inc
50.34
Table…acts 265 — 265 Total revenues $ 294,282 $ 179,278 $ 115,004 The following table summarizes revenues from each of our customers who individually accounted for 10% or more of the total net product sales and revenues from collaborations
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| McKesson Corporation | 42% | 45% |
basisRIGL FY2025 revenue $294M
RIGL 10-Kaccession 0001034842-26-000015
Table…acts 265 — 265 Total revenues $ 294,282 $ 179,278 $ 115,004 The following table summarizes revenues from each of our customers who individually accounted for 10% or more of the total net product sales and revenues from collaborations
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cencora Inc. | 19% | 20% |
basisRIGL FY2025 revenue $294M
RIGL 10-Kaccession 0001034842-26-000015
SentenceAs of December 31, 2024, we have a contractual commitment related to our sublease agreement with Atara for approximately $0.3 million, payable through the expiration of the sublease agreement in May 2025.
RIGL 10-Kaccession 0001558370-25-002169
SentenceFurther, in February 2024, we entered into an Asset Purchase Agreement with Blueprint to purchase certain assets comprising the right to research, develop, manufacture and commercialize GAVRETO, Blueprint's proprietary RET inhibitor of tyrosine kinase for the treatment of metastatic RET fusion-positive NSCLC and advanced thyroid cancer, in the US.
RIGL 10-Kaccession 0001558370-25-002169
SentenceUnder the collaboration, we will provide CONNECT with funding up to $3.0 million and study material over the four-year collaboration.
RIGL 10-Kaccession 0001034842-26-000015
SentenceIn July 2022, we entered into a license and transition services agreement with Forma for an exclusive license to develop, manufacture and commercialize olutasidenib, a proprietary inhibitor of mIDH1, for any uses worldwide, including for the treatment of AML and other malignancies.
RIGL 10-Kaccession 0001558370-25-002169
SentenceUnder the Strategic Collaboration Agreement, we will provide MDACC the study materials and $15.0 million in time-based milestone payments as compensation for services to be provided for the studies, over the five-year collaboration term, unless terminated earlier as provided for in the agreement.
RIGL 10-Kaccession 0001034842-26-000015
SentenceWe have received payments from our current collaborations including Lilly, Grifols, Kissei, Medison, Knight, BerGenBio, and Daiichi.
RIGL 10-Kaccession 0001558370-25-002169
SentenceGovernment contracts revenue in 2023 comprised $1.0 million of government award granted to us by the US Department of Defense (DOD) to support our Phase 3 clinical trial to evaluate the safety and efficacy of fostamatinib in hospitalized COVID-19 patients, and $0.1 million award granted to us by Biomedical Advanced Research and Development (BARDA), part of the Office of the Assistant Secretary for the Preparedness and Response at the DHHS for our evaluation of fostamatinib in mitigating the impact of long-term respiratory distress.
RIGL 10-Kaccession 0001558370-25-002169
SentenceCardinal Health, Inc. * 13%
RIGL 10-Kaccession 0001034842-26-000015
SentenceWe have received payments from our current collaborations including Lilly, Grifols, Kissei, Medison, Knight, BerGenBio, and Daiichi.
RIGL 10-Kaccession 0001558370-25-002169
SentenceWe have received payments from our current collaborations including Lilly, Grifols, Kissei, Medison, Knight, BerGenBio, and Daiichi.
RIGL 10-Kaccession 0001558370-25-002169
SentenceWe have received payments from our current collaborations including Lilly, Grifols, Kissei, Medison, Knight, BerGenBio, and Daiichi.
RIGL 10-Kaccession 0001558370-25-002169
SentenceWe have received payments from our current collaborations including Lilly, Grifols, Kissei, Medison, Knight, BerGenBio, and Daiichi.
RIGL 10-Kaccession 0001558370-25-002169
SentenceWe have received payments from our current collaborations including Lilly, Grifols, Kissei, Medison, Knight, BerGenBio, and Daiichi.
RIGL 10-Kaccession 0001558370-25-002169
SentenceWe have received payments from our current collaborations including Lilly, Grifols, Kissei, Medison, Knight, BerGenBio, and Daiichi.
RIGL 10-Kaccession 0001558370-25-002169
SentenceGovernment contracts revenue in 2023 comprised $1.0 million of government award granted to us by the US Department of Defense (DOD) to support our Phase 3 clinical trial to evaluate the safety and efficacy of fostamatinib in hospitalized COVID-19 patients, and $0.1 million award granted to us by Biomedical Advanced Research and Development (BARDA), part of the Office of the Assistant Secretary for the Preparedness and Response at the DHHS for our evaluation of fostamatinib in mitigating the impact of long-term respiratory distress.
RIGL 10-Kaccession 0001558370-25-002169
Expected move
Inputs8Q avg ±11.0%·×0.99·fair
straddle ±12.8%
spot 51.31exp Nov 20ATM strike 50ATM straddle 7.75IV 79%